These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37149546)

  • 21. Feasibility of S-1 adjuvant chemotherapy after major hepatectomy for biliary tract cancers: An exploratory subset analysis of JCOG1202.
    Kobayashi S; Nakachi K; Ikeda M; Konishi M; Ogawa G; Sugiura T; Yanagimoto H; Morinaga S; Wada H; Shimada K; Takahashi Y; Nakagohri T; Kamata K; Shimizu Y; Ajiki T; Hirano S; Gotohda N; Ueno M; Okusaka T; Furuse J
    Eur J Surg Oncol; 2024 Feb; 50(2):107324. PubMed ID: 38157649
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adjuvant and neoadjuvant chemotherapy for biliary tract cancer: a review of randomized controlled trials.
    Nakachi K; Gotohda N; Hatano E; Nara S; Takahashi S; Kawamoto Y; Ueno M
    Jpn J Clin Oncol; 2023 Nov; 53(11):1019-1026. PubMed ID: 37599063
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reevaluating Adjuvant Capecitabine for Resected Biliary Tract Cancer.
    Benjamin DJ; Prasad V
    Oncologist; 2024 Feb; 29(2):100-101. PubMed ID: 37682029
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Role of chemotherapy in treatments for biliary tract cancer.
    Furuse J; Kasuga A; Takasu A; Kitamura H; Nagashima F
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):337-41. PubMed ID: 22456744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Adjuvant treatment of biliary tract cancers: Who and how?].
    Edeline J
    Bull Cancer; 2020 Jan; 107(1):48-53. PubMed ID: 31980143
    [TBL] [Abstract][Full Text] [Related]  

  • 26. ASO Author Reflections: Characteristics of Surgery for Biliary Tract Cancer that Should be Considered During the Design of Future Clinical Trials.
    Kobayashi S; Ikeda M; Nakachi K; Ueno M; Okusaka T; Todaka A; Satoi S; Tomokuni A; Konishi M; Furuse J
    Ann Surg Oncol; 2023 Nov; 30(12):7384-7385. PubMed ID: 37442909
    [No Abstract]   [Full Text] [Related]  

  • 27. A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in patients with biliary tract cancer undergoing curative resection without major hepatectomy (KHBO1202).
    Yanagimoto H; Toyokawa H; Sakai D; Wada H; Satoi S; Yamamoto T; Nagano H; Toyoda M; Ajiki T; Satake H; Tsuji A; Miyamoto A; Tsujie M; Takemura S; Yanagihara K; Ioka T
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):461-468. PubMed ID: 29305639
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Indications for neoadjuvant, adjuvant, and palliative chemotherapy in the treatment of biliary tract cancers.
    Huitzil-Melendez FD; O'Reilly EM; Duffy A; Abou-Alfa GK
    Surg Oncol Clin N Am; 2009 Apr; 18(2):361-79, x. PubMed ID: 19306817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Meta-analysis of randomized clinical trials of adjuvant chemotherapy for resected biliary tract cancers.
    Ma WJ; Jin YW; Wu ZR; Yang Q; Wang JK; Liu F; Shi YJ; Li QS; Cheng NS
    HPB (Oxford); 2020 Jul; 22(7):939-949. PubMed ID: 32349925
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A systematic review and network meta-analysis of adjuvant therapy for curatively resected biliary tract cancers.
    Kish M; Chan K; Perry K; Ko YJ
    Curr Oncol; 2020 Feb; 27(1):e20-e26. PubMed ID: 32218664
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regional chemotherapy in biliary tract cancers--a single institution experience.
    Melichar B; Cerman J; Dvorák J; Jandík P; Mergancová J; Melicharová K; Tousková M; Krajina A; Voboril Z
    Hepatogastroenterology; 2002; 49(46):900-6. PubMed ID: 12143237
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adjuvant chemotherapy with gemcitabine and S-1 after surgical resection for advanced biliary carcinoma: outcomes and prognostic factors.
    Murakami Y; Uemura K; Sudo T; Hashimoto Y; Nakashima A; Sakabe R; Kobayashi H; Kondo N; Nakagawa N; Sueda T
    J Hepatobiliary Pancreat Sci; 2012 Jul; 19(4):306-13. PubMed ID: 22270151
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The impact of S-1 for the patient with lymph nodal metastasis biliary tract cancer as adjuvant chemotherapy: a multicenter database analysis.
    Hamura R; Haruki K; Taniai T; Yanagaki M; Shirai Y; Furukawa K; Usuba T; Fujioka S; Okamoto T; Nakabayashi Y; Uwagawa T; Ikegami T
    Int J Clin Oncol; 2022 Jul; 27(7):1188-1195. PubMed ID: 35426581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
    Nakachi K; Ikeda M; Konishi M; Nomura S; Katayama H; Kataoka T; Todaka A; Yanagimoto H; Morinaga S; Kobayashi S; Shimada K; Takahashi Y; Nakagohri T; Gotoh K; Kamata K; Shimizu Y; Ueno M; Ishii H; Okusaka T; Furuse J;
    Lancet; 2023 Jan; 401(10372):195-203. PubMed ID: 36681415
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adjuvant chemotherapy in biliary tract cancer patients: A systematic review and meta-analysis of randomized controlled trials.
    Caparica R; Bruzzone M; Hachem GE; Ceppi M; Lambertini M; Glasberg J; de Azambuja E; Van Laethem JL; Hendlisz A
    Crit Rev Oncol Hematol; 2020 May; 149():102940. PubMed ID: 32252001
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The efficacy of fluoropyrimidine-based adjuvant chemotherapy on biliary tract cancer after R0 resection.
    Kim YS; Jeong CY; Song HN; Kim TH; Kim HJ; Lee YJ; Hong SC
    Chin J Cancer; 2017 Jan; 36(1):9. PubMed ID: 28086990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effectiveness of omega-3 fatty acid administration on completion rate of adjuvant chemotherapy for biliary tract cancer: study protocol for a single-centre, open-label, single-arm, historically controlled study.
    Ueno K; Ajiki T; Tsugawa D; Akita M; Hashimoto Y; Awazu M; Mukubo H; Komatsu S; Kuramitsu K; Terai S; Tanaka M; Toyama H; Kido M; Fukumoto T
    BMJ Open; 2019 Aug; 9(8):e029915. PubMed ID: 31401605
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of 5-fluorouracil based adjuvant therapy in resected biliary tract cancer: A systematic review and meta-analysis.
    Song S; Yang W; Tian H; Gong S; Lei C; Lv K; Lu T; Cheng Q; Yang K; Guo T
    Clin Res Hepatol Gastroenterol; 2022 Feb; 46(2):101788. PubMed ID: 34389530
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Trends in Receipt of Adjuvant Chemotherapy and its Impact on Survival in Resected Biliary Tract Cancers.
    Rhodin KE; Liu A; Bartholomew A; Kramer R; Parameswaran A; Uronis H; Strickler J; Hsu D; Morse MA; Shah KN; Herbert G; Zani S; Nussbaum DP; Allen PJ; Lidsky ME
    Ann Surg Oncol; 2023 Aug; 30(8):4813-4821. PubMed ID: 37188803
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study.
    Edeline J; Benabdelghani M; Bertaut A; Watelet J; Hammel P; Joly JP; Boudjema K; Fartoux L; Bouhier-Leporrier K; Jouve JL; Faroux R; Guerin-Meyer V; Kurtz JE; Assénat E; Seitz JF; Baumgaertner I; Tougeron D; de la Fouchardière C; Lombard-Bohas C; Boucher E; Stanbury T; Louvet C; Malka D; Phelip JM
    J Clin Oncol; 2019 Mar; 37(8):658-667. PubMed ID: 30707660
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.